Jan 17, 2014 2:20 pm EST NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014
Jan 7, 2014 7:00 am EST NeoGenomics is the First Laboratory to Offer Calreticulin (CALR) Mutation Testing for the Diagnosis and Classification of Myeloproliferative Neoplasms
Oct 23, 2013 7:00 am EDT NeoGenomics Reports Record Revenue of $16.9 Million, Adjusted EBITDA of $2.2 Million and Net Income of $900K for the Third Quarter 2013
Jul 31, 2013 7:00 am EDT NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013
Jul 25, 2013 7:00 am EDT NeoGenomics Introduces Comprehensive Myelodysplastic Syndrome (MDS) Molecular Testing
Apr 25, 2013 7:00 am EDT NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter
